Biotech

Page 15 of 18

Symbolic - biotechnology - genetic engineering
Tech

Guess What This Early Skype Investor Is Betting on Now

By
February 2, 2016
Key Speakers At The Stanford Institute For Economic Policy Research Forum
Leadership

Gilead CEO John Martin Is Stepping Down After 20 Years

By
January 29, 2016
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance

Biotech Stocks Crashed and Nobody Knows Why

By
January 29, 2016
Biosimilars Are Coming After Big Pharma’s Bottom Line
Health

Biosimilars Are Coming After Big Pharma’s Bottom Line

By
January 12, 2016
AbbVie Inc. To Buy Shire For $54.8 Billion
International

Shire-Baxalta $32 Billion Merger Talks Said to Advance

By
January 3, 2016
Biotech’s Insane Year
Health

Biotech’s Insane Year

By
December 31, 2015
Inside of a Gilead Sciences Lab
Finance

Isis Pharmaceuticals Changes Its Name After Terrorists Attack Stock Price

By
December 18, 2015
Packs of Wrigley chewing gum are displayed in Westerville, O
Tech

Doublemint Gum Is an Awesome Biosensor

By
December 3, 2015
MSMB Capital Management CIO Martin Shkreli
Finance

Turing CEO Invested in This Penny Stock Biotech to Keep It Alive

By
November 19, 2015
CNBC Events - Clinton Global Initiative 2015
Tech

A Theranos Deal With Safeway Stores May be Falling Apart

By
November 11, 2015
BRITAIN-PHARMA-BUSINESS-ASTRAZENECA
Health

Astrazeneca is Buying ZS Pharma for $2.7 billion

By
November 6, 2015
MSMB Capital Management CIO Martin Shkreli
Health

This super-expensive drug is getting a $1 rival

By
October 23, 2015
Big pharma won’t stay silent in drug pricing debate for long
Health

Big pharma won’t stay silent in drug pricing debate for long

By
October 22, 2015
Biogen Idec Inc. CEO George Scangos Interview
Health

Profits up, Biogen cuts 11% of global workforce

By
October 21, 2015
Hillary Clinton in the first Democratic presidential debate in Las Vegas on Oct. 13
Commentary

Clinton’s big pharma takedown plan has some serious issues

By Chris Ford and Bethany Cianciolo
October 16, 2015

Most Popular